VIA
CELU icon

Vident Investment Advisory’s Celularity CELU Stock Holding History

Vident Investment Advisory’s Portfolio CELU Stock Details CELU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-14,930
Closed -$345K – 1199
2022
Q3 		$345K Sell
14,930
-1,600
-10% -$48.6K 0.01% 862
2022
Q2 		$562K Buy
+16,530
New +$1.34M 0.02% 839

Other funds holding CELU

SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
CVSC
C.V. Starr & Co New York $187M AUM 26.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Vident Investment Advisory's CELU Position: Q4 2022 in Review

Vident Investment Advisory sold out of Celularity (CELU) in Q4 2022, closing a stake of 14,930 shares — an estimated $345K sold.

Vident Investment Advisory first reported a position in CELU in Q2 2022 and held it in 2 quarters. The position peaked at $562K in Q2 2022. 73 funds tracked by Wall St. Rank hold CELU as of Q4 2022.

  • Vident Investment Advisory reported no remaining Celularity position as of Q4 2022 after selling out during the quarter.
  • Vident Investment Advisory sold 14,930 Celularity shares in Q4 2022, an estimated $345K.
  • Vident Investment Advisory first reported a position in Celularity in Q2 2022 and held it in 2 quarters.
  • Vident Investment Advisory's Celularity position peaked at $562K in Q2 2022.
  • 73 funds tracked by Wall St. Rank held Celularity as of Q4 2022.

Based on Vident Investment Advisory's 13F filing for Q4 2022, filed 14 Feb 2023.